GPA booster.

Non-small cell lung cancer (NSCLC) has been needing one for years. The current graded prognostic assessment is based on outcomes dating back to the 1980s. More recent data (read: from this millennium) on 2186 patients with newly-diagnosed NSCLC brain mets were analyzed with the additional prognostic factors of EGFR and ALK alterations. Remarkably, those with higher (3.5-4.0) Lung-molGPA scores had a median survival approaching 4 years--as compared to 14 months among top-scorers in the current DS-GPA. Now that is a 4.0 worthy of recognition.